Newly Approved Drug Therapies (581) Evista (raloxifene hydrochloride), Eli Lilly,

The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Drug Info

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.

Home » Drug Information » FDA-Approved Drugs » 1999
Medical Areas: Endocrinology | Musculoskeletal | Obstetrics/Gynecology

View By: Year Company Therapeutic Areas Drug Names

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: Evista (raloxifene hydrochloride)

Company: Eli Lilly
Approval Status: Approved September 1999
Treatment Area: For the treatment of osteoporosis in postmenopausal women.

General Information

Tablet of raloxifene hydrochloride for the treatment of osteoporosis in post-menopausal women.

Mechanism of Action

Tablet, 60 mg.

Privacy |
Glossary